Delta-9-tetrahydrocannabinol, neural oscillations above 20 Hz and induced acute psychosis
Judith Nottage, James Stone, Robin Murray, Alexander Luke Sumich, Elvira Bramon, Dominic H Ffytche, Paul D. Morrison
Psychopharmacology July 19, 2014 DOI: 10.1007/s00213-014-3684-1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Double-blind crossover study Peer reviewed |
|---|---|
| Sample size | 15 |
| Population | Healthy participants given intravenous THC or placebo (13 crossover pairs plus 4 THC-only for resting EEG; 15 for the motor task) |
| Intervention | delta-9-tetrahydrocannabinol (THC) |
| Measures | Positive and Negative Syndrome Scale (PANSS) |
| Topics | Cannabis |
| Citations | 34 |
| Key points | Intravenous THC shifted resting EEG toward higher frequencies, reducing 21-27 Hz and increasing 27-45 Hz magnitude, and this effect correlated with PANSS positive symptoms (r = 0.429). THC also increased 65-130 Hz event-related synchronization over contralateral sensorimotor areas, driven by the 85-130 Hz band. The authors propose this faster-gamma shift may reflect cortical over-activation possibly related to saliency misattribution in delusions. |
Abstract
Rationale: An acute challenge with delta-9-tetrahydrocannabinol (THC) can induce psychotic symptoms including delusions. High electroencephalography (EEG) frequencies, above 20 Hz, have previously been implicated in psychosis and schizophrenia.
Objectives: The objective of this study is to determine the effect of intravenous THC compared to placebo on high-frequency EEG.
Methods: A double-blind cross-over study design was used. In the resting state, the high-beta to low-gamma magnitude (21-45 Hz) was investigated (n = 13 pairs + 4 THC only). Also, the event-related synchronisation (ERS) of motor-associated high gamma was studied using a self-paced button press task (n = 15).
Results: In the resting state, there was a significant condition × frequency interaction (p = 0.00017), consisting of a shift towards higher frequencies under THC conditions (reduced high beta [21-27 Hz] and increased low gamma [27-45 Hz]). There was also a condition × frequency × location interaction (p = 0.006), such that the reduction in 21-27-Hz magnitude tended to be more prominent in anterior regions, whilst posterior areas tended to show greater 27-45-Hz increases. This effect was correlated with positive symptoms, as assessed on the Positive and Negative Syndrome Scale (PANSS) (r = 0.429, p = 0.042). In the motor task, there was a main effect of THC to increase 65-130-Hz ERS (p = 0.035) over contra-lateral sensorimotor areas, which was driven by increased magnitude in the higher, 85-130-Hz band (p = 0.02) and not the 65-85-Hz band.
Conclusions: The THC-induced shift to faster gamma oscillations may represent an over-activation of the cortex, possibly related to saliency misattribution in the delusional state.
Comparable studies
Other randomized controlled trials on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Healthy participants | 2012 | Randomized controlled trial | n = 48 |
| Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing Healthy, English-native, right-handed men who had used cannabis 15 times or less in... | 2009 | Double-blind, randomized, placebo-controlled crossover trial | n = 15 |
| Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers Healthy male subjects | 2012 | Randomized controlled trial | n = 16 |
| Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol Healthy, native English-speaking, right-handed men of white race/ethnicity who had used... | 2009 | Randomized controlled trial | n = 15 |
| Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition Healthy volunteers with a history of light cannabis use | 2019 | Randomized, double-blind, within-subjects crossover | n = 14 |
Citations in the library
Cited by 8
- Human Laboratory Studies on Cannabinoids and Psychosis. Biological Psychiatry April 1, 2016
- Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research Frontiers in Pharmacology June 21, 2017
- Mood Fluctuation and Psychobiological Instability: The Same Core Functions Are Disrupted by Novel Psychoactive Substances and Established Recreational Drugs Brain Sciences March 13, 2018
- Brain Changes during Cannabis-Induced Psychosis: Clarifying the Marijuana Medicine/Harm Dichotomy Journal of psychiatry and brain science 2018
- Convergence of Cannabis and Psychosis on the Dopamine System JAMA Psychiatry April 9, 2025
and 3 more in the library
Cites 15
- Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. American Journal of Psychiatry 2003
- Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids Behavioural Pharmacology September 1, 2005
- Familial Predisposition for Psychiatric Disorder Archives of General Psychiatry November 3, 2008
- The effect of chronic cannabinoids on broadband EEG neural oscillations in humans. Neuropsychopharmacology September 2012
- Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ⁹-THC in humans. Neuropsychopharmacology June 2012
and 10 more in the library